| Dolutegravir plus two different prodrugs of tenofovir to treat HIV WDF Venter, M Moorhouse, S Sokhela, L Fairlie, N Mashabane, ... New England Journal of Medicine 381 (9), 803-815, 2019 | 620 | 2019 |
| Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial … WDF Venter, S Sokhela, B Simmons, M Moorhouse, L Fairlie, ... The lancet HIV 7 (10), e666-e676, 2020 | 225 | 2020 |
| Weight and metabolic changes after switching from tenofovir alafenamide/emtricitabine (FTC)+ dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+ DTG, and TDF/FTC … B Bosch, G Akpomiemie, N Chandiwana, S Sokhela, A Hill, K McCann, ... Clinical Infectious Diseases 76 (8), 1492-1495, 2023 | 32 | 2023 |
| High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa N Chandiwana, S Sawry, M Chersich, E Kachingwe, B Makhathini, ... Medicine 97 (29), e10901, 2018 | 31 | 2018 |
| Impact of long-acting therapies on the global HIV epidemic NC Chandiwana, CM Serenata, A Owen, S Rannard, CP Casas, C Scott, ... Aids 35 (Supplement 2), S137-S143, 2021 | 28 | 2021 |
| Guidelines to support HIV-affected individuals and couples to achieve pregnancy safely: update 2018 NECG Davies, G Ashford, LG Bekker, N Chandiwana, D Cooper, SJ Dyer, ... Southern African Journal of HIV Medicine 19 (1), 1-26, 2018 | 28 | 2018 |
| AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised … GO Griffiths, R FitzGerald, T Jaki, A Corkhill, H Reynolds, S Ewings, ... Trials 22, 1-5, 2021 | 23 | 2021 |
| Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa NC Chandiwana, M Chersich, WDF Venter, G Akpomiemie, A Hill, ... AIDS 35 (2), 205-211, 2021 | 18 | 2021 |
| Weight gain stopping/switch rules for antiretroviral clinical trials WDF Venter, S Sokhela, A Calmy, L Mkhondwane, B Bosch, ... Aids 35 (Supplement 2), S183-S188, 2021 | 17 | 2021 |
| Weight gain after HIV therapy initiation: pathophysiology and implications NC Chandiwana, MJ Siedner, VC Marconi, A Hill, MK Ali, RL Batterham, ... The Journal of Clinical Endocrinology & Metabolism 109 (2), e478-e487, 2024 | 16 | 2024 |
| Final week 192 results from the ADVANCE trial: first-line TAF/FTC+ DTG, TDF/FTC+ DTG vs TDF/FTC/EFV WDF Venter, B Bosch, S Sokhela, G Akpomiemie, N Chandiwana, ... Aids, 2022 | 14 | 2022 |
| The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine … S Asif, E Baxevanidi, A Hill, WDF Venter, L Fairlie, M Masenya, ... Aids 35 (Supplement 2), S117-S125, 2021 | 13 | 2021 |
| Erratum: Southern African HIV Clinicians Society 2022 guideline for the management of sexually transmitted infections: Moving towards best practice RPH Peters, N Garret, N Chandiwana, R Kularatne, AJ Brink, K Cohen, ... Southern African Journal of HIV Medicine 23 (1), 2022 | 12 | 2022 |
| Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 … N Chandiwana, C Kruger, H Johnstone, MF Chughlay, C Ju, B Kim, ... EBioMedicine 86, 2022 | 11 | 2022 |
| Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries K Steegen, N Chandiwana, S Sokhela, WDF Venter, L Hans Aids 37 (6), 1009-1011, 2023 | 8 | 2023 |
| Genetic associations with weight gain among South Africans who initiated dolutegravir-containing and tenofovir-containing regimens Z Cindi, G Maartens, Y Bradford, WDF Venter, S Sokhela, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 87 (3), 1002-1009, 2021 | 8 | 2021 |
| Drug resistance and use of long-acting ART J da Silva, M Siedner, S McCluskey, N Chandiwana, F Venter, E Raizes The Lancet HIV 9 (6), e374-e375, 2022 | 6 | 2022 |
| Final 192-week efficacy and safety results of the ADVANCE trial, comparing 3 first-line antiretroviral regimens S Sokhela, WDF Venter, B Bosch, J Woods, K McCann, G Akpomiemie, ... Open Forum Infectious Diseases 11 (3), ofae007, 2024 | 5 | 2024 |
| Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population AN Kawuma, RE Wasmann, P Sinxadi, SM Sokhela, N Chandiwana, ... CPT: Pharmacometrics & Systems Pharmacology 12 (6), 821-830, 2023 | 5 | 2023 |
| Pharmacogenetics of dolutegravir plasma exposure among southern Africans with human immunodeficiency virus Z Cindi, AN Kawuma, G Maartens, Y Bradford, F Venter, S Sokhela, ... The Journal of infectious diseases 226 (9), 1616-1625, 2022 | 5 | 2022 |
